Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 Dec 2006

Abstract excerpt

The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17185464
DOI: 10.1182/blood-2006-09-044974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibPMID 17185464Read ↗

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple MyelomaSemantic proximity Read ↗

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Semantic proximity Read ↗

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.Semantic proximity Read ↗

Inflammatory microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myelomaSemantic proximity Read ↗

Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple MyelomaSemantic proximity Read ↗

Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.Semantic proximity Read ↗

The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype.Semantic proximity Read ↗

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity Read ↗

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and TherapySemantic proximity Read ↗

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma ModelSemantic proximity Read ↗

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with BortezomibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.